Otonomy, Inc. (OTIC)
| Market Cap | 120.56M |
| Revenue (ttm) | 273,000 |
| Net Income (ttm) | -44.73M |
| Shares Out | 40.85M |
| EPS (ttm) | -1.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 8 |
| Last Price | $2.56 |
| Previous Close | $2.50 |
| Change ($) | 0.06 |
| Change (%) | 2.40% |
| Day's Open | 2.50 |
| Day's Range | 2.45 - 2.60 |
| Day's Volume | 539,885 |
| 52-Week Range | 1.53 - 6.98 |
Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...
Otonomy Inc (NASDAQ: OTIC) has reported topline data from Phase 3 trial evaluating OTIVIDEX in patients with Ménière's disease. It is an inner ear disorder that causes episodes of vertigo (spi...
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...
Conference call and webcast today at 4:30 p.m. ET
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...
OTIC failed a phase 3 trial and fell from $20 to $5, and hasn't recovered since despite succeeding in another phase 3. A tiebreaker third phase 3 is ongoing with data by 1Q2021.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...
Otonomy (OTIC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided u...
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...
Otonomy, Inc. (OTIC) CEO David Weber on Q3 2020 Results - Earnings Call Transcript
Otonomy (OTIC) delivered earnings and revenue surprises of 12.00% and -54.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Otonomy, Inc. (OTIC) CEO David Weber On Q3 2020 Results - Quick Version Earnings Call Transcript
Shares of Otonomy (NASDAQ:OTIC) were flat after the company reported Q3 results. Quarterly Results Earnings per share were up 33.33% over the past year to ($0.22), which beat the estimate of (...
Conference call and webcast today at 4:30 p.m. ET
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...
SAN DIEGO, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...
Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announc...
Otonomy, Inc. (OTIC) CEO David Weber on Q2 2020 Results - Earnings Call Transcript
Otonomy (OTIC) delivered earnings and revenue surprises of -2.78% and -92.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Compound has potential to benefit patients with severe hearing loss Compound has potential to benefit patients with severe hearing loss
Webcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020 Webcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020
SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announce...
Otonomy (OTIC) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announce...
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announce...
Otonomy (NASDAQ: OTIC) shares are trading higher on Tuesday. The company reported results from its Phase 1/2 clinical trial of OTO-313 in patients with Tinnitus demonstrated a higher proportio...
SAN DIEGO, July 06, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announce...
Management will review the OTIVIDEX statistical analysis plan update together with the positive top-line OTO-313 Phase 1/2 trial results during a conference call today at 4:30 p.m. ET Manageme...
Conference call and webcast today at 4:30 p.m. ET
Otonomy (OTIC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announce...
SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announce...
Conference call to review status of clinical trials and timing to results to be held in June Conference call to review status of clinical trials and timing to results to be held in June
SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provid...
Otonomy's (OTIC) CEO David Weber on Q4 2019 Results - Earnings Call Transcript
Otonomy (OTIC) delivered earnings and revenue surprises of 23.40% and -15.46%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.
SAN DIEGO, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announce...
Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease
As of late, it has definitely been a great time to be an investor in Otonomy.
Top Ranked Momentum Stocks to Buy for December 3rd
Otonomy's (OTIC) CEO David Weber on Q3 2019 Results - Earnings Call Transcript
Otonomy (OTIC) delivered earnings and revenue surprises of 26.67% and -59.68%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Otonomy (OTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Initial focus on GJB2, the most common cause of genetic hearing loss in newborns Initial focus on GJB2, the most common cause of genetic hearing loss in newborns
About OTIC
Otonomy, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical tria... [Read more...]
| Industry Biotechnology | IPO Date Aug 13, 2014 |
| CEO David Weber | Employees 56 |
| Stock Exchange NASDAQ | Ticker Symbol OTIC |
Financial Performance
In 2020, Otonomy's revenue was $273,000, a decrease of -54.50% compared to the previous year's $600,000. Losses were -$44.73 million, 0.13% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for Otonomy stock is "Strong Buy." The 12-month stock price forecast is 5.38, which is an increase of 110.16% from the latest price.